Phenformin
- Generic Name
- Phenformin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H15N5
- CAS Number
- 114-86-3
- Unique Ingredient Identifier
- DD5K7529CE
- Background
A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
- Indication
For the reatment of type II diabetes mellitus.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03026517
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath